Replies to post #19175 on The Rising Influence of Rising Affluence

[biotech_researcher]

CLB -Core Labs- A premier company in it day, but it is still overvalued..... Was $121 in October last year, today it is $54. PE of 25 is still way to high, especially knowing the trailing 12 mo. earnings were $2.15 and the dividend is $2.20.

Something has to give.

[DewDiligence]

CLB 2Q19 CC transcript:

https://finance.yahoo.com/news/core-laboratories-nv-clb-q2-212338873.html

[DewDiligence]

CLB 3Q19 results—revenue +2.5% QoQ—EPS=$0.50:

https://finance.yahoo.com/news/core-lab-reports-third-quarter-211500018.html

The 3Q19 revenue of $173M and GAAP EPS of $0.50 (excluding $0.04 of special items) are right smack in the middle of the prior guidance ranges of $171-175M and $0.48-0.52.

(That kind of precision is sort of GE scary, LOL.)

The guidance for 4Q19 is: revenue of $161-163M, and GAAP EPS of $0.44-0.45. Given such weak guidance, I would have expected the stock to be down in the AH session, but it’s actually up 2%.

CC tomorrow at 8:30am ET.